TABLE 7.
Antibiotic combination regimens in three groups of patients in the quadruple therapy.
| Regimen | Basis for treatment | Overall (n = 36), n (%) | ||
|
| ||||
| DST (n = 12), n (%) | PCR (n = 12), n (%) | WGS (n = 12), n (%) | ||
| TET + FZD | 1 (8.3) | 2 (16.7) | 1 (8.3) | 4 (11.1) |
| TET + MTZ | 1 (8.3) | 1 (8.3) | 2 (16.7) | 4 (11.1) |
| AMX + FZD | 7 (58.3) | 3 (25.0) | 6 (50.0) | 16 (44.4) |
| AMX + LVX | 3 (25.0) | 6 (50.0) | 3 (25.0) | 12 (33.3) |
AMX, amoxicillin; LVX, levofloxacin; MTZ, metronidazole; TET, tetracycline; FZD, furazolidone. DST, drug susceptibility testing; PCR, polymerase chain reaction; WGS, whole genome sequencing.